Latest News

Oral TLR7/8 inhibitor enpatoran earns FDA Breakthrough status for lupus skin disease, with Phase 2 CLASI-A gains and Phase 3 underway.

Findings from an independent, blinded re-adjudication of ADVOCATE's primary endpoints will be presented at an FDA hearing scheduled for July 2026.

With structural inhibition now in the label, Mease explains why radiographic protection matters as a treatment goal and what it means to have that evidence for an IL-23 inhibitor.

Key changes in the 2026 ACR/SAA/SPARTAN guideline update elevate JAK inhibitors to a strong recommendation and introduce nociplastic pain guidance.

Emanuel Della-Torre, MD, PhD, discusses the largest randomized controlled trial in IgG4-RD establishing proof of concept for B-cell inhibition.

Iain McInnes, MD, PhD, discussed comparing bimekizumab and risankizumab for PsA.

In the FIBRONEER-ILD autoimmune ILD subgroup, nerandomilast attenuated FVC decline and nominally reduced all-cause mortality risk at both doses.

Philip Mease, MD, discusses BE BOLD, which delivers the first head-to-head superiority result for a joint-focused endpoint in psoriatic arthritis.

Richard Furie, MD, discusses phase 2 JASMINE data showing sustained SRI-4 and LLDAS responses through 52 weeks.

Phase 2b/3 data show durable ACR50/70, PASI90/100, and minimal disease activity responses with izokibep through one year.

Check out what coverage RheumLive has slated for the upcoming congress in London.

Guselkumab (Tremfya) was originally approved in 2020, with its indication expanded to pediatric patients with psoriatic arthritis in 2025.

Findings will be presented at the EULAR Annual Meeting and show significantly more bimekizumab-treated patients achieved the 16 week ACR50 primary endpoint.

New JIA guidance urges early biologics, favors oral methotrexate, adds mental health screening, and reshapes tapering and monitoring.

Phase 2/3 China trial shows IL‑17A antibody vunakizumab rapidly improves radiographic axSpA symptoms vs placebo, with benefits lasting to 32 weeks.

The new approval is backed by ADAPT SERON results showing significant MG-ADL improvement and consistent safety.

April is Sjögren's Awareness Month and we took a look at how the field's fast-growing pipeline is reshaping care.

The FDA approved anifrolumab via a once-weekly subcutaneous autoinjector for moderate to severe SLE based on phase 3 TULIP-SC trial results.

FDA reviews Gazyva for systemic lupus after ALLEGORY shows stronger responses, fewer flares and steroid use—potential first anti‑CD20 option for SLE.

Experts discuss CTD-ILD guidance and nerandomilast reshape screening, progression monitoring, and multidisciplinary treatment.

Real-world data suggest IL-23 biologics may cut 3-year psoriatic arthritis risk in psoriasis versus TNF and IL-17 therapies.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Additional data from the BE BOLD trial supporting bimekizumab over risankizumab are slated for a future medical conference.